Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RAD51C E80* |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RAD51C E80* | ovarian carcinoma | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 | |
| RAD51C E80* | ovarian carcinoma | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 |
| RAD51C E80* | ovarian carcinoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 | |
| RAD51C E80* | ovarian carcinoma | sensitive | Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, Zejula (niraparib) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 | |
| RAD51C E80* | ovarian carcinoma | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 | |
| RAD51C E80* | ovarian carcinoma | sensitive | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, Veliparib (ABT-888) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C E80* in culture (PMID: 28588062). | 28588062 |